<DOC>
	<DOC>NCT00792558</DOC>
	<brief_summary>The purpose of this study is to find the maximum tolerated dose of BMS-817378 in subjects with advanced cancers</brief_summary>
	<brief_title>Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis of advanced nonhematologic malignancy. Dose expansion cohort restricted to subjects with advanced or metastatic gastroesophageal cancer, squamous cell cancers of the head and neck, and castration resistant prostate cancer ECOG status 01 WOCBP unwilling/unable to use acceptable contraception methods, and women pregnant or breast feeding Symptomatic brain metastasis Uncontrolled or significant cardiovascular disease History of thromboembolic events or bleeding diathesis in past 6 months Conditions requiring prophylactic anticoagulation or chronic antiplatelet therapy Serious nonhealing wounds, ulcers or bone fractures in past 3 months Hemorrhage or bleeding event &gt;= CTCAE grade 3 in past 4 weeks Proteinuria &gt;= 2+ on dipstick or &gt;= 1gm/24 hours Concurrent chemotherapy, hormonal therapy, immunotherapy, radiation therapy or therapy with any other investigational product Concurrent herbal, alternative, food supplements, or strong CYP 3A4 inhibitors or inducers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>